Shinobi Therapeutics

Welcome Masashi Ochi and Eiki Maeda to the Shinobi Therapeutics leadership team! Eiki and Ochi bring significant experience in developing cell therapies and will support execution of our lead programs. Follow Shinobi Therapeutics for more exciting updates as we continue to advance the next generation of immune evasive iPSC-derived cell therapies.

We are proud to share that Shinobi Therapeutics has secured a $59M grant from the Japanese Agency for Medical Research and Development (AMED) to advance our lead iPS-T cell program targeting GPC3+ tumors! We are also thrilled to welcome Yosemite and Mitsubishi UFJ Capital Co.,Ltd. to our investor syndicate, bringing our total funding to $119M. This funding is a significant step towards our vision of transforming cancer care with immune-evasive cell therapies, and fuels our mission to bring groundbreaking, off-the-shelf cell therapies to patients worldwide. Press release: https://lnkd.in/ejje3H-p Endpoints article: https://lnkd.in/eKZgxiVf

I’ve spent a significant amount of time in Japan over the past few years …. in some ways it’s my second home. To see Prime Minister Kishida himself, mention our company Shinobi Therapeutics this week in a public address is a great honor to say the least. This shout-out is not only massively validating, but also underscores the bright future of biotech collaboration between Japan, the US and the global community. We’ve been working hard, and being recognized like this for our pioneering iPS cell technology, that we grew out of Kyoto University is pretty empowering. Stretching across the Pacific, from our HQs in SF and Kyoto, we’ve got a clear bridge between these two worlds. We’re more committed now than ever to leading the charge in transforming patient care through groundbreaking R&D https://lnkd.in/dJscDSWY

We are excited to share our new partnership with Anocca to develop TCR-iPS-T-cell therapies for the treatment of solid tumors! Learn more about our collaboration and synergistic technologies below??

We are attending #BIO2024! Meet with our CEO, Dan Kemp, and Head of BD and R&D Strategy, Molly Cole, to discuss partnering opportunities. Learn more about how we are pioneering the next frontier of cell therapy with our comprehensive immune evasion "Evade" technology and "Katana" iPS-T platform at https://www.shinobitx.com/. We look forward to connecting in San Diego!

Earlier this year I attended the ITMAT Kyoto University International Symposium held in collaboration with the University of Pennsylvania. The symposium featured two days of fantastic talks around the theme Biology of Human Diseases Comes of Age. Carl June gave a captivating overview of CAR T cells in cancer and beyond, underscoring the potential of CAR-Ts in treating autoimmunity, chronic infections, and many other conditions. At Shinobi Therapeutics we are helping to fulfill this potential by advancing the next generation of cell therapies. Our plug-and-play CD8ab iPS-T "Katana" platform and comprehensive immune evasion “Evade” technology solve key challenges in the field, and we are thrilled to be working with Carl June to develop game-changing therapies. Shinobi Therapeutics CEO Dan Kemp and I will be at Biotechnology Innovation Organization?next month and are eager to talk with potential partners. Please reach out if you would like to learn more and meet up in San Diego! #BIO2024

Appreciate Fierce Pharma for recognizing the importance of engineering the future of cell therapy manufacturing. Our collaboration with Panasonic is a key step for Shinobi Therapeutics. https://lnkd.in/ekJx4aA9

We are excited to share that?we have partnered with?Panasonic to support development of an automated closed-system device that will utilize Shinobi’s proprietary CD8ab iPS-T cell differentiation process. The full potential of cell therapies cannot be realized without manufacturing at scale and low cost,?and manufacturing at scale is ultimately an engineering challenge. We believe that?working with a world-renowned technology partner?like Panasonic will?enable the next generation of cell therapies and expand patient access. Read more in our press release: https://lnkd.in/eXfBAX9N

Carl June joined our team in Kyoto this week to kick off our SAB along with Shinobi co-founder SHIN KANEKO. We aligned on how Shinobi's technology differentiates itself in the allogeneic space, and discussed opportunities to leverage our hypoimmune iPS-T cells to treat autoimmune diseases and solid tumors. Stay tuned for further updates on our progress!

One of the biggest challenges in the cell therapy field is allo-rejection, where the patient's immune system targets the allogeneic cell therapy as a foreign invader?before it has a chance?to do its job. Shinobi's "Evade" technology is the most comprehensive approach to genetically?protect allogeneic cell therapies from attack?by the patient's T cells, NK cells, macrophages, and even antibodies. Our latest publication in Cell Stem Cell highlights the power of our hypoimmune technology. We believe that application of our "Evade" technology to iPS-derived, as well as primary allogeneic cell therapies, will be a game-changer. Link to publication:?https://lnkd.in/eVSBjzKk